Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

por Kubota, Y., Kawazoe, A., Mishima, S., Nakamura, Y., Kotani, D., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Yoshino, T., Kuwata, T., Shitara, K.
Publicado 2023

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

por Yokota, T, Ura, T, Shibata, N, Takahari, D, Shitara, K, Nomura, M, Kondo, C, Mizota, A, Utsunomiya, S, Muro, K, Yatabe, Y
Publicado 2011

Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer

por Shitara, K, Yuki, S, Tahahari, D, Nakamura, M, Kondo, C, Tsuda, T, Kii, T, Tsuji, Y, Utsunomiya, S, Ichikawa, D, Hosokawa, A, Ishiguro, A, Sakai, D, Hironaka, S, Oze, I, Matsuo, K, Muro, K
Publicado 2014

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

por Van Cutsem, E., Hochster, H., Shitara, K., Mayer, R., Ohtsu, A., Falcone, A., Yoshino, T., Doi, T., Ilson, D.H., Arkenau, H.-T., George, B., Benhadji, K.A., Makris, L., Tabernero, J.
Publicado 2022

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

por Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.
Publicado 2021

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study...

por Van Cutsem, E., Valderrama, A., Bang, Y.-J., Fuchs, C.S., Shitara, K., Janjigian, Y.Y., Qin, S., Larson, T.G., Shankaran, V., Stein, S., Norquist, J.M., Kher, U., Shah, S., Alsina, M.
Publicado 2021

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

por Okamoto, W., Sakai, K., Makiyama, A., Yamamoto, Y., Shitara, K., Denda, T., Izawa, N., Nakano, Y., Nishina, T., Esaki, T., Hara, H., Miura, Y., Boku, N., Yamazaki, K., Hironaka, S., Misumi, T., Hyodo, I., Muro, K., Nishio, K.
Publicado 2022